I am the Head of AI/ML Product at Absci, where I lead a team of AI Scientists, Software Engineers, Computational Biologists, and Product Managers in building and experimentally validating generative AI tools for therapeutic antibody design. I hope our technology will enable us to develop cures for diseases that have historically remained intractable. We recently launched Origin-1, our first AI platform for de novo antibody drug design.
Previously I was an AI/ML Product Manager at PathAI, where I led product development and translational science for their flagship AI digital pathology products in metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), a liver disease with poor prognosis. I hope that the tools we built will help identify effective therapies and improve outcomes for MASH patients. One of them has recently been qualified by the FDA for clinical trial endpoint assessment.
Prior to joining PathAI, I completed a PhD in Speech and Hearing Bioscience and Technology (SHBT) at Harvard University. I designed, fabricated, and patented an endomicroscope that visualizes cells inside the cochlea — the small, snail-shaped organ that shelters the primary sensory receptors for hearing. I hope that our device will improve diagnostics for deafness, the most common sensory deficit in the world.
